Hyderabad based Biological E. Limited (BE) on Friday announced that its Typhoid Conjugate Vaccine (TCV) has been pre-qualified by the World Health Organisation. With this pre-qualification, BE became one of two pre-qualified suppliers of TCV to the UN agencies. BE’s TCV is a single-dose injectable vaccine, which can be administered to children from 6 months of age to adults up to the age of 45 and it is formulated with Vi polysaccharide conjugated to a carrier protein (CRM197). The Vi polysaccharide antigen used in BE’s TCV is derived from C.freundii, which is a non-pathogenic source (BSL 1 organism), compared to virulent Salmonella Typhii used by other manufacturers, and the carrier protein used for conjugation is a non-toxic CRM197 protein locally developed by BE through in-house R&D effort. Clinical studies conducted in India have shown that the safety and immunogenicity profiles of this vaccine are comparable with those of the other WHO pre-qualified TCV. BE offers this vaccine as single-dose and multi-dose vials for ease of administration.
Courtesyg: Google (photo)
